COPENHAGEN Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy. As a monotherapy, Keytruda halved the risk of disease progression and cut overall deaths by 40 percent compared to […]
